Suppr超能文献

基于甲基化的乳腺癌化疗耐药中微小RNA 320a调控网络

A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.

作者信息

He Dong-Xu, Gu Xiao-Ting, Jiang Li, Jin Jian, Ma Xin

机构信息

National Engineering Laboratory for Cereal Fermentation Technology (D.X.H.), and Department of Cellular and Molecular Pharmacology, School of Medicine and Pharmaceutics (X.T.G., L.J., J.J., X.M.), Jiangnan University, Wuxi, People's Republic of China.

National Engineering Laboratory for Cereal Fermentation Technology (D.X.H.), and Department of Cellular and Molecular Pharmacology, School of Medicine and Pharmaceutics (X.T.G., L.J., J.J., X.M.), Jiangnan University, Wuxi, People's Republic of China

出版信息

Mol Pharmacol. 2014 Nov;86(5):536-47. doi: 10.1124/mol.114.092759. Epub 2014 Aug 26.

Abstract

We previously demonstrated that the overexpression of transient receptor potential channel C5 (TRPC5) and nuclear factor of activated T-cells isoform c3 (NFATC3) are essential for cancer chemoresistance, but how TRPC5 and NFATC3 are regulated was still unclear. In this study, microRNA 320a (miR-320a) was found to be down-regulated in chemoresistant cancer cells. MiR-320a directly targeted TRPC5 and NFATC3, and down-regulation of miR-320a triggered TRPC5 and NFATC3 overexpression. In chemoresistant cells, down-regulation of miR-320a was associated with regulation by methylation, which implicated promoter methylation of the miR-320a coding sequence. Furthermore, the transcription factor v-ets erythroblastosis virus E26 oncogene homolog 1 (ETS-1), which inhibited miR-320a expression, was activated in chemoresistant cancer cells; such activation was associated with hypomethylation of the ETS-1 promoter. Lastly, the down-regulation of miR-320a and high expression of TRPC5, NFATC3, and ETS-1 were verified in clinically chemoresistant samples. Low expression of MiR-320a was also found to be a significant unfavorable predictor for clinic outcome. In conclusion, miR-320a is a mediator of chemoresistance by targeting TRPC5 and NFATC3. Expression of miR-320a is regulated by methylation of its promoter and that of ETS-1.

摘要

我们之前证明,瞬时受体电位通道C5(TRPC5)的过表达和活化T细胞核因子c3亚型(NFATC3)对癌症化疗耐药性至关重要,但TRPC5和NFATC3如何被调控仍不清楚。在本研究中,发现微小RNA 320a(miR-320a)在化疗耐药癌细胞中表达下调。miR-320a直接靶向TRPC5和NFATC3,miR-320a的下调引发TRPC5和NFATC3的过表达。在化疗耐药细胞中,miR-320a的下调与甲基化调控有关,这意味着miR-320a编码序列的启动子甲基化。此外,抑制miR-320a表达的转录因子v-ets成红细胞增多症病毒E26癌基因同源物1(ETS-1)在化疗耐药癌细胞中被激活;这种激活与ETS-1启动子的低甲基化有关。最后,在临床化疗耐药样本中验证了miR-320a的下调以及TRPC5、NFATC3和ETS-1的高表达。还发现miR-320a低表达是临床预后的一个显著不利预测指标。总之,miR-320a通过靶向TRPC5和NFATC3是化疗耐药的一个介质。miR-320a的表达受其启动子以及ETS-1启动子甲基化的调控。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验